Inactive Instrument

Neutra Corp Stock Other OTC

US64129C2044

Pharmaceuticals

End-of-day quote Other OTC Other stock markets
- ^USD	-

25-03-31	Neutra Corp. executed a letter of intent to acquire CuraConnector.com, Inc.	CI
24-08-07	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI

Neutra Corp. is an early-stage research and development company. The Company is engaged in marketing and participating in the nutraceutical space by bringing products derived from all natural and organic origins. The Company plans to research and bring new technology to the Nutraceutical space. The Company is primarily focused on participating in the medical cannabis market, which is a nutraceutical sub-market. It intends to entrust the manufacturing to a nutraceutical contractor to private label all of its products and to sell them under its brand. It primarily sells hemp-derived products, including products containing delta-8-THC and other cannabinoids. Its subsidiaries include Diamond Anvil Designs, LLC, Deity Corporation and Vivis Corporation.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	460K 402K 371K 342K 645K 44.31M 659K 4.44M 1.74M 21.7M 1.73M 1.69M 74.71M	P/E 2023	-1.94x	P/E 2024	-3.75x
Enterprise Value	525K 458K 423K 390K 735K 50.52M 751K 5.06M 1.99M 24.74M 1.97M 1.93M 85.18M	EV / Sales 2023	18,402,377x	EV / Sales 2024	23,773,714x
Free-Float	99.31%	Yield 2023 *	-	Yield 2024	-

25-03-31	Neutra Corp. executed a letter of intent to acquire CuraConnector.com, Inc.	CI
24-08-07	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
24-08-02	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2024	CI
23-12-15	Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	CI
23-09-14	Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	CI
23-06-22	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2023	CI
23-06-09	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2023	CI
23-06-08	Neutra Corp. Auditor Raises 'Going Concern' Doubt	CI
23-01-29	Neutra Corp. executed a binding letter of intent to acquire Mercury Clinical Research, Inc.	CI
22-12-15	Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	CI
22-09-14	Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	CI
22-06-21	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2022	CI
22-05-10	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2022	CI

07-13	Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth	AQ
06-29	Neutra Corp’s Subsidiary Neutra Life Sciences Executes New Women’s Health Joint Venture and Expands Trial Portfolio	AQ
01-19	Neutra Corp Successfully Pivots Into New Business Vertical With Projected Over 1,000% Revenue Increase Year-Over-Year	AQ
25-10-13	Neutra Corp's Subsidiary, Neutra Life Sciences, Adds to Its Site Network With New Joint Venture Partnership in Family Medicine	AQ
25-08-25	Neutra Corp Launches Corporate Rebranding Initiative, Unveils New Logo, New Website, and Strengthens Focus on Life Sciences Through Its SMO	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.85%	-0.80%	+52.79%	+159.97%	1,051B
JOHNSON & JOHNSON	+1.23%	-1.53%	+54.58%	+59.41%	609B
ABBVIE INC.	+0.04%	+2.58%	+34.47%	+84.84%	450B
ROCHE HOLDING AG	-0.01%	+1.12%	+30.83%	+22.13%	330B
NOVARTIS AG	-0.54%	-0.18%	+35.84%	+36.73%	284B
ASTRAZENECA PLC	+0.06%	+0.02%	+23.26%	+17.91%	263B
NOVO NORDISK A/S	+0.62%	+2.42%	-19.14%	-39.82%	223B
AMGEN INC.	-1.42%	+0.80%	+24.27%	+57.85%	198B
GILEAD SCIENCES, INC.	-1.48%	+3.43%	+24.08%	+70.06%	167B
Average	-0.27%	+0.54%	+29.00%	+52.12%	397.23B
Weighted average by Cap.	-0.06%	+0.02%	+37.83%	+78.10%

	2023	2024
Net sales	0.07 0.06 0.05 0.05 0.1 6.55 0.1 0.66 0.26 3.21 0.26 0.25 11.04	0.04 0.03 0.03 0.03 0.06 3.81 0.06 0.38 0.15 1.86 0.15 0.15 6.42
Net income	-561K -491K -453K -417K -787K -54.07M -804K -5.41M -2.13M -26.48M -2.11M -2.06M -91.15M	-233K -204K -188K -174K -327K -22.48M -334K -2.25M -885K -11.01M -877K -858K -37.91M
Net Debt	54.5K 47.63K 43.95K 40.51K 76.36K 5.25M 78.05K 525K 207K 2.57M 205K 200K 8.85M	64.5K 56.37K 52.01K 47.94K 90.37K 6.21M 92.37K 622K 245K 3.04M 242K 237K 10.47M

Neutra Corp Stock Other OTC

Stocks

US64129C2044

Pharmaceuticals

Valuation: Neutra Corp

Latest news : Neutra Corp

Press Releases: Neutra Corp

Managers and Directors: Neutra Corp

Other Pharmaceuticals

Financials

Company Profile